Get access

The influence of comorbid MDD on outcome after residential treatment for veterans with PTSD and a history of TBI

Authors

  • Kristen H. Walter,

    1. Cincinnati VA Medical Center, PTSD & Anxiety Disorders Clinic, Cincinnati, Ohio, USA
    Search for more papers by this author
  • Sean M. Barnes,

    1. Cincinnati VA Medical Center, PTSD & Anxiety Disorders Clinic, Cincinnati, Ohio, USA
    2. VA Eastern Colorado Health Care System, VISN 19 Mental Illness Research Education and Clinical Center, Denver, Colorado, USA
    Search for more papers by this author
  • Kathleen M. Chard

    Corresponding author
    1. Cincinnati VA Medical Center, PTSD & Anxiety Disorders Clinic, Cincinnati, Ohio, USA
    2. University of Cincinnati School of Medicine, Department of Psychiatry, Cincinnati, Ohio, USA
    • Cincinnati VA Medical Center, 3200 Vine Street, Cincinnati, Ohio 45220.
    Search for more papers by this author

  • We would like to thank the staff of the Cincinnati VAMC PTSD & Anxiety Disorders Clinic for their efforts with data collection and for the outstanding care they provide to veterans. We would also like to thank David Greenwald, PhD, and Misty Wolfe, MPH, for their assistance with this manuscript.

Abstract

Among military personnel, posttraumatic stress disorder (PTSD), major depressive disorder (MDD), and a history of traumatic brain injury (TBI) are frequently reported, highlighting the need for treatment outcome research with this population. This study examined the influence of the presence or absence of comorbid MDD on the outcome of a residential treatment program at the midpoint and end of the program for 47 male veterans with PTSD and a history of TBI. Results demonstrated significant decreases of self-reported symptoms on the PTSD Checklist-Stressor Specific Version (PCL-S; MDD, d = 1.19; No MDD, d = 1.17) and the Beck Depression Inventory–II (BDI-II; MDD, d = 0.98; No MDD, d = 1.09) following treatment for both groups. There were no differences in the rate of symptom reduction between groups. Individuals who also met criteria for MDD at pretreatment, however, evidenced higher scores on symptom measures at all assessment time points (ds = 0.60–1.25).

Get access to the full text of this article

Ancillary